NanoViricides is trading 13.79% up at $1.62 as investor interest builds around its Phase II NV-387 oral-gummy Ebola trial.
- The study is scheduled to begin during the week of September 21, 2026, in the Democratic Republic of Congo.
- It will initially evaluate safety and dosing before efficacy testing.
- The catalyst follows regulatory approval and trial registration, with broader risk-on markets providing additional support.